140 related articles for article (PubMed ID: 8895744)
1. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history.
Bennett WP; von Brevern MC; Zhu SM; Bartsch H; Muehlbauer KR; Hollstein MC
Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):963-6. PubMed ID: 9367071
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
4. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
5. p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China.
Wang LD; Zhou Q; Hong JY; Qiu SL; Yang CS
Cancer; 1996 Apr; 77(7):1244-9. PubMed ID: 8608498
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
8. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
[TBL] [Abstract][Full Text] [Related]
9. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
10. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
11. [Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer].
Muzeau F; Fléjou JF; Potet F; Belghiti J; Thomas G; Hamelin R
Gastroenterol Clin Biol; 1996; 20(5):430-7. PubMed ID: 8761140
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between serum p53 antibody and chemosensitivity in patient with esophageal cancer].
Wang MH; Li YP; Wang XD; Zhang H; Xiong LH; Huang HZ
Ai Zheng; 2004 Apr; 23(4):467-70. PubMed ID: 15087041
[TBL] [Abstract][Full Text] [Related]
13. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between p53 nuclear protein accumulation and mutations of the p53 gene in human esophageal cancer from linxian].
Liang Y; Lu S; Guo Y
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):412-4. PubMed ID: 8697989
[TBL] [Abstract][Full Text] [Related]
15. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma.
Limpaiboon T; Sripa B; Wongkham S; Bhudhisawasdi V; Chau-in S; Teerajetgul Y
Hepatogastroenterology; 2004; 51(55):25-8. PubMed ID: 15011824
[TBL] [Abstract][Full Text] [Related]
16. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
Lutz W; Nowakowska-Swirta E
Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
[TBL] [Abstract][Full Text] [Related]
17. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
18. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
Casson AG; Evans SC; Gillis A; Porter GA; Veugelers P; Darnton SJ; Guernsey DL; Hainaut P
J Thorac Cardiovasc Surg; 2003 May; 125(5):1121-31. PubMed ID: 12771886
[TBL] [Abstract][Full Text] [Related]
20. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status.
Volkmann M; Müller M; Hofmann WJ; Meyer M; Hagelstein J; Räth U; Kommerell B; Zentgraf H; Galle PR
Hepatology; 1993 Sep; 18(3):559-65. PubMed ID: 7689531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]